Physician
RPK Center for Rehab, Spine & Pain
RPK Center for Rehab, Spine & Pain was paid $1.97M by Medicaid between Jan 2018 and Dec 2024, across 17 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 27% of everything it billed.
33Billing provider infoRPK CENTER FOR REHAB, SPINE & PAIN
FAYETTEVILLE, NC 28304
FAYETTEVILLE, NC 28304
33aNPI1093778110assigned 04/10/2006
33bProvider typePhysical Medicine & Rehabilitation Physician
28Total paid$1.97M
24GClaims38,251
24DCodes billed17
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physical Medicine & Rehabilitation Physician providers in North Carolina
Rank by total paid#4 of 42
Median peer was paid$18K
This provider vs. median112×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,907 | $203K | |
| 2019 | 6,083 | $278K | |
| 2020 | 5,943 | $270K | |
| 2021 | 7,304 | $369K | |
| 2022 | 5,948 | $356K | |
| 2023 | 4,538 | $298K | |
| 2024incomplete | 3,528 | $193K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 27% | 9,662 | 7,966 | $537K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26% | 13,797 | 11,663 | $506K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22% | 7,697 | 6,597 | $439K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 14% | 2,359 | 1,502 | $266K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.7% | 885 | 823 | $74K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.9% | 913 | 543 | $58K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.9% | 1,007 | 801 | $57K |
| 62323 | <1% | 82 | 81 | $10K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,075 | 959 | $6K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 61 | 55 | $3K |
| 99441 | <1% | 401 | 262 | $3K | |
| 95886 | <1% | 41 | 38 | $3K |
5 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKISHBAUGH, DAVID (MANAGER-MEMBER/OWNER)